News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
717,210 Results
Type
Article (65838)
Company Profile (401)
Press Release (650971)
Section
Business (206032)
Career Advice (2415)
Deals (34718)
Drug Delivery (93)
Drug Development (83400)
Employer Resources (152)
FDA (16345)
Job Trends (15053)
News (347569)
Policy (31548)
Tag
Academia (2873)
Alliances (52714)
Alzheimer's disease (1311)
Approvals (16274)
Artificial intelligence (146)
Bankruptcy (299)
Best Places to Work (11602)
Biotechnology (274)
Breast cancer (123)
Cancer (1117)
Cardiovascular disease (104)
Career advice (2025)
Cell therapy (256)
Clinical research (65518)
Collaboration (400)
Compensation (180)
COVID-19 (2737)
C-suite (103)
Data (1129)
Diabetes (152)
Diagnostics (6321)
Earnings (80544)
Employer resources (136)
Events (112775)
Executive appointments (312)
FDA (16877)
Funding (352)
Gene therapy (183)
GLP-1 (636)
Government (4159)
Healthcare (18897)
Infectious disease (2827)
Inflammatory bowel disease (118)
Interviews (431)
IPO (16312)
Job creations (3857)
Job search strategy (1740)
Layoffs (445)
Legal (7161)
Lung cancer (174)
Manufacturing (191)
Medical device (13556)
Medtech (13560)
Mergers & acquisitions (18515)
Metabolic disorders (428)
Neuroscience (1601)
NextGen Class of 2024 (6546)
Non-profit (4651)
Northern California (1478)
Obesity (238)
Opinion (222)
Patents (105)
People (58447)
Phase I (20397)
Phase II (28754)
Phase III (21486)
Pipeline (461)
Postmarket research (2870)
Preclinical (9236)
Radiopharmaceuticals (256)
Rare diseases (226)
Real estate (6225)
Regulatory (21552)
Research institute (2614)
Resumes & cover letters (365)
Southern California (1303)
Startups (3812)
United States (13596)
Vaccines (643)
Weight loss (192)
Date
Today (146)
Last 7 days (901)
Last 30 days (3824)
Last 365 days (36913)
2024 (33638)
2023 (41377)
2022 (52662)
2021 (57170)
2020 (55297)
2019 (47558)
2018 (36131)
2017 (34330)
2016 (34279)
2015 (40482)
2014 (33709)
2013 (29653)
2012 (30553)
2011 (30709)
2010 (29025)
Location
Africa (954)
Arizona (165)
Asia (43127)
Australia (7542)
California (3340)
Canada (1265)
China (254)
Colorado (146)
Connecticut (153)
Europe (98548)
Florida (449)
Georgia (121)
Illinois (344)
Indiana (200)
Kansas (101)
Maryland (585)
Massachusetts (2666)
Michigan (166)
Minnesota (280)
New Jersey (962)
New York (948)
North Carolina (779)
Northern California (1478)
Ohio (143)
Pennsylvania (814)
South America (1259)
Southern California (1303)
Texas (459)
Utah (91)
Washington State (372)
717,210 Results for "rinat pfizer global research and development".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Vaccines
UK Patent Win Over GSK Boosts Pfizer in Global RSV Vaccine Fight
A judge in the U.K. last month sided with Pfizer over GSK in a respiratory syncytial virus vaccine patent lawsuit, positioning both companies to compete for that market and laying down a marker for ongoing legal clashes in other parts of the world.
November 20, 2024
·
4 min read
·
Nick Paul Taylor
Sickle cell disease
Pfizer Takes Sickle Cell Drug Oxbryta Off Global Market, Cites Risk of Death
Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in patients with sickle cell disease. Guggenheim Securities analysts said the setback increases investor frustrations with the company’s business development track record.
September 26, 2024
·
2 min read
·
Tristan Manalac
Drug development
5 Sickle Cell Therapies to Watch Following Pfizer’s Oxbryta Exit
In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy,
BioSpace
looks at five investigational drugs currently making their way through the pipeline.
October 21, 2024
·
4 min read
·
Kate Goodwin
Podcast
BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day
Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; new IVF and abortion laws could derail women’s health research; Roche touts CDK inhibitor deal and obesity pipeline and
BioSpace
heads to Meeting on the Mesa.
October 2, 2024
·
1 min read
·
Heather McKenzie
Business
Department of Health - Abu Dhabi Partners with Pfizer to Advance Research in Sickle Cell Disease and Beyond
The Department of Health – Abu Dhabi, the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding with Pfizer Gulf FZ LLC, a global pharmaceutical company during BIO 2024 International Convention.
June 3, 2024
·
4 min read
Drug Development
ATTR-CM Approval for BridgeBio Could Trigger Tight Race with Pfizer
Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than Pfizer’s already established tafamidis.
November 19, 2024
·
6 min read
·
Heather McKenzie
Sickle Cell Disease
Pfizer’s Oxbryta Withdrawal Leaves Sickle Cell Community Scrambling, Investors Reeling
Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in sales by the end of the decade, has left patients and healthcare providers with few options, while investors question the pharma giant’s dealmaking prowess.
September 27, 2024
·
7 min read
·
Annalee Armstrong
Podcast
Pfizer’s Q3 Earnings Win, Deals Galore, Countdown to Election, More
Pfizer, Sanofi and others report Q3 beats; AbbVie, Roche and Novartis strike big deals; the 2024 presidential election looms; and
BioSpace
takes a look back at 10 years of NextGen, our annual pick of young biotechs to watch.
October 30, 2024
·
1 min read
·
Heather McKenzie
Editorial
Analysts Rally Around Pfizer CEO Amid Starboard Challenge
Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the company’s leadership. However, analysts are supportive of the embattled executive.
October 25, 2024
·
4 min read
·
Greg Slabodkin
RSV
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age. Tuesday’s label expansion covers younger adults who are deemed at higher risk of RSV-related lower respiratory tract disease.
October 23, 2024
·
2 min read
·
Tristan Manalac
1 of 71,721
Next
